{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T23:27:05Z","timestamp":1776382025761,"version":"3.51.2"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T00:00:00Z","timestamp":1669334400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006939","name":"Emory University","doi-asserted-by":"publisher","award":["P30CA138292"],"award-info":[{"award-number":["P30CA138292"]}],"id":[{"id":"10.13039\/100006939","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,3,17]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Biomarkers have the potential to guide treatment selection and clinical care in metastatic renal cell carcinoma (mRCC) in an expanding treatment landscape. We report baseline neutrophil-to-eosinophil ratios (NER) in patients with mRCC treated with immune checkpoint inhibitors (CPIs) and their association with clinical outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a retrospective review of patients with mRCC treated with CPIs at Winship Cancer Institute from 2015 to 2020 in the United States of America (USA). Demographics, disease characteristics, and laboratory data, including complete blood counts (CBC) were described at the initiation of CPIs. Clinical outcomes were measured as overall survival (OS), progression-free survival (PFS), and clinical benefit (CB) associated with baseline lab values.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 184 patients were included with a median follow-up time of 25.4 months. Patients with baseline NER were categorized into high or low subgroups; high group was defined as NER &amp;gt;49.2 and low group was defined as NER &amp;lt;49.2 with 25% of patients in the high NER group. Univariate analyses (UVA) and multivariable analyses (MVA) identified decreased overall survival (OS) associated with elevated NER. In MVA, patients with a high baseline NER group had a hazard ratio (HR) of 1.68 (95%CI, 1.01-2.82, P = .048) for OS; however, there was no significant difference between groups for PFS. Clinical benefit was seen in 47.3% of patients with low baseline NER and 40% with high NER.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>We conclude that elevated baseline NER may be associated with worse clinical outcomes in mRCC. Although results require further validation, NER is a feasible biomarker in patients with CPI-treated mRCC.<\/jats:p><\/jats:sec>","DOI":"10.1093\/oncolo\/oyac236","type":"journal-article","created":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T16:07:09Z","timestamp":1669392429000},"page":"239-245","source":"Crossref","is-referenced-by-count":13,"title":["Baseline Neutrophil-to-Eosinophil Ratio Is Associated with Outcomes in Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors"],"prefix":"10.1093","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1729-4629","authenticated-orcid":false,"given":"Tony Z","family":"Zhuang","sequence":"first","affiliation":[{"name":"Department of Medicine, Emory University School of Medicine , Atlanta, GA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepak","family":"Ravindranathan","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Emory University School of Medicine , Atlanta, GA , USA"},{"name":"Grady Cancer Center for Excellence, Grady Memorial Hospital , Atlanta, GA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Liu","sequence":"additional","affiliation":[{"name":"Departments of Biostatistics and Bioinformatics, Emory University , Atlanta, GA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dylan J","family":"Martini","sequence":"additional","affiliation":[{"name":"Department of Medicine, Massachusetts General Hospital , Boston, MA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacqueline T","family":"Brown","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Emory University School of Medicine , Atlanta, GA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6385-1329","authenticated-orcid":false,"given":"Bassel","family":"Nazha","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Emory University School of Medicine , Atlanta, GA , USA"},{"name":"Grady Cancer Center for Excellence, Grady Memorial Hospital , Atlanta, GA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Greta","family":"Russler","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Emory University School of Medicine , Atlanta, GA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren B","family":"Yantorni","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Emory University School of Medicine , Atlanta, GA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Caulfield","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Emory University School of Medicine , Atlanta, GA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bradley C","family":"Carthon","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Emory University School of Medicine , Atlanta, GA , USA"},{"name":"Grady Cancer Center for Excellence, Grady Memorial Hospital , Atlanta, GA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omer","family":"Kucuk","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Emory University School of Medicine , Atlanta, GA , USA"},{"name":"Grady Cancer Center for Excellence, Grady Memorial Hospital , Atlanta, GA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viraj A","family":"Master","sequence":"additional","affiliation":[{"name":"Department of Urology, Emory University School of Medicine , Atlanta, GA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehmet Asim","family":"Bilen","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Emory University School of Medicine , Atlanta, GA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,11,25]]},"reference":[{"key":"2023041012091156900_","author":"SEER.","year":"2021"},{"issue":"1","key":"2023041012091156900_","doi-asserted-by":"crossref","first-page":"71","DOI":"10.6004\/jnccn.2022.0001","article-title":"Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology","volume":"20","author":"Motzer","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"issue":"4","key":"2023041012091156900_","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMra1601333","article-title":"Systemic therapy for metastatic renal-cell carcinoma","volume":"376","author":"Choueiri","year":"2017","journal-title":"N Engl J Med"},{"issue":"14","key":"2023041012091156900_","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"N Engl J Med"},{"issue":"12","key":"2023041012091156900_","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med"},{"issue":"9","key":"2023041012091156900_","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"2023041012091156900_","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1093\/oncolo\/oyab056","article-title":"First-line treatments for metastatic clear cell renal cell carcinoma: an ever-enlarging landscape","volume":"27","author":"Gulati","year":"2022","journal-title":"Oncologist"},{"issue":"12","key":"2023041012091156900_","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.3390\/cancers14122867","article-title":"Metastatic clear-cell renal cell carcinoma in the era of immune checkpoint inhibitors: \u00adtherapies and ongoing trials","volume":"14","author":"Zhuang","year":"2022","journal-title":"Cancers"},{"issue":"Suppl 3","key":"2023041012091156900_","first-page":"A154","article-title":"255 Efficacy of sequential immune checkpoint","volume":"8","author":"Evans","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2023041012091156900_","first-page":"133","article-title":"Phase II trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) for progressive disease after PD-1\/PD-L1 immune checkpoint inhibitor (ICI) in metastatic clear cell (mcc) renal cell carcinoma (RCC): Results by independent imaging review and subgroup analyses","author":"Lee","year":"2020","journal-title":"Asia-Pacific J Clin Oncol."},{"issue":"10","key":"2023041012091156900_","doi-asserted-by":"crossref","first-page":"e1742","DOI":"10.1002\/onco.13868","article-title":"Immune-related adverse events as clinical biomarkers in patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors","volume":"26","author":"Martini","year":"2021","journal-title":"Oncologist"},{"key":"2023041012091156900_","doi-asserted-by":"crossref","first-page":"707050","DOI":"10.3389\/fonc.2021.707050","article-title":"Bodym composition variables as radiographic biomarkers of clinical outcomes in metastatic renal cell carcinoma patients receiving immune checkpoint inhibitors","volume":"11","author":"Martini","year":"2021","journal-title":"Front Oncol"},{"key":"2023041012091156900_","doi-asserted-by":"crossref","first-page":"779915","DOI":"10.3389\/fendo.2022.779915","article-title":"Advances in knowledge and management of immune-related adverse events in cancer immunotherapy","volume":"13","author":"Olsen","year":"2022","journal-title":"Front Endocrinol"},{"key":"2023041012091156900_","doi-asserted-by":"crossref","first-page":"701345","DOI":"10.3389\/fonc.2021.701345","article-title":"Racial differences in clinical outcomes for metastatic renal cell carcinoma patients treated with immune-checkpoint blockade","volume":"11","author":"Olsen","year":"2021","journal-title":"Front Oncol"},{"issue":"15_suppl","key":"2023041012091156900_","doi-asserted-by":"crossref","first-page":"e16570","DOI":"10.1200\/JCO.2021.39.15_suppl.e16570","article-title":"Clinical outcomes in metastatic renal cell carcinoma (mRCC) treated with combination of nivolumab and cabozantinib (nivo-cabo) in the salvage setting","volume":"39","author":"Ravindranathan","year":"2021","journal-title":"J Clin Oncol"},{"issue":"7","key":"2023041012091156900_","doi-asserted-by":"crossref","first-page":"e002851","DOI":"10.1136\/jitc-2021-002851","article-title":"Modified Glasgow Prognostic Score associated with survival in metastatic renal cell carcinoma treated with immune checkpoint inhibitors","volume":"9","author":"Brown","year":"2021","journal-title":"J ImmunoTher Cancer"},{"issue":"3","key":"2023041012091156900_","doi-asserted-by":"crossref","first-page":"52","DOI":"10.36401\/JIPO-22-2","article-title":"Combination immune checkpoint blockade regimens previously untreated metastatic renal cell carcinoma: The Winship Cancer Institute of Emory University Experience","volume":"5","author":"Martini","year":"2022","journal-title":"J Immunother Precision Oncol."},{"issue":"5","key":"2023041012091156900_","doi-asserted-by":"crossref","first-page":"S685","DOI":"10.1016\/j.annonc.2021.08.057","article-title":"661P Conditional survival and 5-year follow-up in CheckMate 214: first-line nivolumab + ipilimumab (N+I) versus sunitinib (S) in advanced renal cell carcinoma (aRCC)","volume":"32","author":"Motzer","year":"2021","journal-title":"Ann Oncol"},{"issue":"15_suppl","key":"2023041012091156900_","doi-asserted-by":"crossref","first-page":"4574","DOI":"10.1200\/JCO.2021.39.15_suppl.4574","article-title":"Efficacy of avelumab + axitinib (A + Ax) versus sunitinib (S) by IMDC risk group in advanced renal cell carcinoma (aRCC): extended follow-up results from JAVELIN Renal 101","volume":"39","author":"Haanen","year":"2021","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"2023041012091156900_","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1200\/JCO.2021.39.15_suppl.4500","article-title":"Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): results from 42-month follow-up of KEYNOTE-426","volume":"39","author":"Rini","year":"2021","journal-title":"J Clin Oncol"},{"issue":"6_suppl","key":"2023041012091156900_","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1200\/JCO.2021.39.6_suppl.308","article-title":"Nivolumab + cabozantinib (NIVO+CABO) versus sunitinib (SUN) for advanced renal cell carcinoma (aRCC): Outcomes by sarcomatoid histology and updated trial results with extended follow-up of CheckMate 9ER","volume":"39","author":"Motzer","year":"2021","journal-title":"J Clin Oncol"},{"issue":"1","key":"2023041012091156900_","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ajur.2015.09.004","article-title":"Elevated preoperative \u00adneutrophil-to-lymphocyte ratio may be associated with decreased overall survival in patients with metastatic clear cell renal cell carcinoma undergoing cytoreductive nephrectomy","volume":"3","author":"Baum","year":"2016","journal-title":"Asian J Urol"},{"issue":"4","key":"2023041012091156900_","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1158\/1078-0432.CCR-21-1688","article-title":"Association of \u00adneutrophil-to-lymphocyte ratio with efficacy of first-line pzavelumab plus axitinib vs. sunitinib in patients with advanced renal cell carcinoma enrolled in the phase III JAVELIN renal 101 trial","volume":"28","author":"Bilen","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"12","key":"2023041012091156900_","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1158\/1078-0432.CCR-15-2412","article-title":"Baseline peripheral blood biomarkers associated with clinical outcome of advanced melanoma patients treated with ipilimumab","volume":"22","author":"Martens","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"45","key":"2023041012091156900_","doi-asserted-by":"crossref","first-page":"79809","DOI":"10.18632\/oncotarget.19748","article-title":"Baseline relative eosinophil count as a predictive biomarker for ipilimumab treatment in advanced melanoma","volume":"8","author":"Ferrucci","year":"2017","journal-title":"Oncotarget"},{"issue":"1955","key":"2023041012091156900_","article-title":"Carrying out streamlined routine data analyses with reports for observational studies: introduction to a series of generic SAS (\u00ae) macros","volume":"7","author":"Liu","year":"2018","journal-title":"F1000Res"},{"issue":"1955","key":"2023041012091156900_","doi-asserted-by":"crossref","first-page":"325","DOI":"10.3390\/biology10040325","article-title":"Inflammatory markers in cancer immunotherapy","volume":"10","author":"Ravindranathan","year":"2021","journal-title":"Biology"},{"issue":"6","key":"2023041012091156900_","doi-asserted-by":"crossref","first-page":"1010428317705511010428317705514","DOI":"10.1177\/1010428317705514","article-title":"Time-dependent effects of prognostic biomarkers of systemic inflammation in patients with metastatic renal cell carcinoma","volume":"39","author":"Harris","year":"2017","journal-title":"Tumor Biol"},{"issue":"1","key":"2023041012091156900_","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/cncr.31778","article-title":"The prognostic and predictive impact of inflammatory biomarkers in patients who have advanced-stage cancer treated with immunotherapy","volume":"125","author":"Bilen","year":"2019","journal-title":"Cancer"},{"issue":"3","key":"2023041012091156900_","doi-asserted-by":"crossref","first-page":"e563","DOI":"10.1016\/j.clgc.2017.12.015","article-title":"Association between pretreatment neutrophil-to-lymphocyte ratio and outcome of patients with metastatic renal-cell carcinoma treated with nivolumab","volume":"16","author":"Bilen","year":"2018","journal-title":"Clin Genitourin Cancer"},{"issue":"10","key":"2023041012091156900_","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.pt.2016.05.004","article-title":"Eosinophils in Helminth Infection: defenders and dupes","volume":"32","author":"Huang","year":"2016","journal-title":"Trends Parasitol"},{"issue":"12","key":"2023041012091156900_","doi-asserted-by":"crossref","first-page":"7443","DOI":"10.4049\/jimmunol.1000446","article-title":"Human eosinophils exert TNF-\u03b1 and granzyme A-mediated tumoricidal activity toward colon carcinoma cells","volume":"185","author":"Legrand","year":"2010","journal-title":"J Immunol"},{"issue":"6","key":"2023041012091156900_","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1111\/gtc.12371","article-title":"CCL11-induced eosinophils inhibit the formation of blood vessels and cause tumor necrosis","volume":"21","author":"Xing","year":"2016","journal-title":"Genes Cells"},{"issue":"2","key":"2023041012091156900_","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2217\/imt-2016-0138","article-title":"Eosinophilic count as a biomarker for prognosis of melanoma patients and its importance in the response to immunotherapy","volume":"9","author":"Moreira","year":"2017","journal-title":"Immunotherapy"},{"issue":"1","key":"2023041012091156900_","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s40364-021-00334-4","article-title":"Association of baseline neutrophil-to-eosinophil ratio with response to nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma","volume":"9","author":"Tucker","year":"2021","journal-title":"Biomarker Res"},{"issue":"16_suppl","key":"2023041012091156900_","doi-asserted-by":"crossref","first-page":"4527","DOI":"10.1200\/JCO.2022.40.16_suppl.4527","article-title":"Association between decline of neutrophil-to-eosinophil ratio (NER) at week 6 after ipilimumab plus nivolumab initiation and improved clinical outcomes in \u00admetastatic renal cell carcinoma (mRCC)","volume":"40","author":"Chen","year":"2022","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"2023041012091156900_","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1200\/JCO.2022.40.16_suppl.3147","article-title":"Construction of a near-term predictive model for irAEs induced by PD-1 inhibitors","volume":"40","author":"Zhang","year":"2022","journal-title":"J Clin Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/28\/3\/239\/49806789\/oyac236.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/28\/3\/239\/49806789\/oyac236.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T04:06:39Z","timestamp":1701230799000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/28\/3\/239\/6847156"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,25]]},"references-count":37,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,11,25]]},"published-print":{"date-parts":[[2023,3,17]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyac236","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,3,1]]},"published":{"date-parts":[[2022,11,25]]}}}